Pharmacology of antiepileptic drugs in the neonatal period and early childhood
Abstract
Te aim of this review article is to elucidate the profound effect of developmental characteristics of newborns and infants on the dosing regimen of antiepileptic drugs (AEDs). AEDs have different mechanisms of action that can broadly be grouped in three categories. Te pharmacokinetics of AEDs are largely affected by developmental changes in absorption, distribution, metabolism and excretion. Te cytochrome P450 enzymes represent an important component of the drug metabolism and vary widely with the child’s development and genetics. In the light of this, an important path is paved by a new science–pharmacogenetics, the study of drug response in relation to specifc genes, which is becoming increasingly important in adjusting the drug dosage. Some recommendations regarding the genetic profle have already been approved but are not yet implemented into daily clinical practice. Considering both, the developmental changes and AED characteristics, an optimal dosage with minimal adverse effects may be achieved.
Downloads
References
Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A defnition and classifcation of status epilepticus--Report of the ILAE Task Force on Classifcation of Status Epilepticus. Epilepsia. 2015; 56 (10): 1515-23.
Lawrence R, Inder T. Neonatal status epilepticus. Semin Pediatr Neurol. 2010; 17 (3): 163-8.
Volpe JJ. Neonatal Seizures. Neurology of the Newborn. 5 ed. Philadelphia: WB Saunders; 2009.
Saliba RM, Annegers JF, Waller DK, Tyson JE, Mizrahi EM. Incidence of neonatal seizures in Harris County, Texas, 1992-1994. Am J Epidemiol. 1999; 150 (7): 763-9.
Neubauer D. Repetitorij otroške nevrologije. Ljubljana: Medicinski razgledi; 2004 .
Paro Panjan D, Neubauer D. Nevrološki pregled novorojenčka. 2. izd. Ljubljana: Medicinski razgledi; 2010.
Wirrell EC. Neonatal seizures: to treat or not to treat? Semin Pediatr Neurol. 2005; 12 (2): 97-105.
Isaeva E, Isaev D, Savrasova A, Khazipov R, Holmes GL. Recurrent neonatal seizures result in long-term increases in neuronal network excitability in the rat neocortex. Eur J Neurosci. 2010; 31 (8): 1446-55.
Neubauer D. Krči v novorojenčkovem obdobju. Slov Pediatr 1994 (1): 56–60.
Paro Panjan D. Potek in prognoza krčev v novorojenčkovem obdobju. Ljubljana: [D. Paro Panjan]; 1997.
Soltirovska-Salamon A, Neubauer D, Petrovcic A, Paro-Panjan D. Risk factors and scoring system as a prognostic tool for epilepsy afer neonatal seizures. Pediatr Neurol. 2014; 50 (1): 77-84.
Plouin PA. Benign familial and non–familial neonatal seizures. Epileptic syndromes in Infancy, Childhood and Adolescence. 4 ed. Montorogue, France: John Libbey Eurotext; 2005.
Fister P, Soltirovska-Salamon A, Debeljak M, Paro-Panjan D. Benign familial neonatal convulsions caused by mutation in KCNQ3, exon 6: a European case. Eur J Paediatr Neurol. 2013; 17 (3): 308-10.
Strazisar BG, Neubauer D, Paro Panjan D, Writzl K. Early-onset epileptic encephalopathy with hearing loss in two siblings with TBC1D24 recessive mutations. Eur J Paediatr Neurol. 2015; 19 (2): 251-6.
Garfnkle J, Shevell MI. Cerebral Palsy, Developmental Delay, and Epilepsy Afer Neonatal Seizures. Pediatr Neurol. 2011; 44 (2): 88-96.
Soltirovska Salamon A, Neubauer D, Paro-Panjan D. Development of epilepsy afer neonatal seizures. Eur J Paediatr Neurol. 2015; 19 (5): 612-3.
Nakamura K, Kato M, Osaka H, Yamashita S, Nakagawa E, Haginoya K, et al. Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome. Neurology. 2013; 81 (11): 992-8.
Sivaswamy L. Approach to neonatal seizures. Clin Pediatr. 2012; 51 (5): 415-25.
Shah DK, Boylan GB, Rennie JM. Monitoring of seizures in the newborn. Arch Dis Child Fetal Neonatal Ed. 2012; 97 (1): 5.
Neubauer D. Krči in epilepsije v novorojenčkovem obdobju in zdravljenje. Med Razgl. 2012; 51: 31-7.
van Rooij LG, Hellstrom-Westas L, de Vries LS. Treatment of neonatal seizures. Semin Fetal Neonatal Med. 2013; 18 (4): 209-15.
Nagarajan L. Neonatal seizures: Current management and future challenges. London: Mac Keith Press; 2016.
Boylan GB, Rennie JM, Chorley G, Pressler RM, Fox GF, Farrer K, et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology. 2004; 62 (3): 486-8.
Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med. 1999; 341 (7): 485-9.
Jensen FE. Neonatal seizures: an update on mechanisms and management. Clin Perinatol. 2009; 36 (4): 881-900, vii.
Volpe JJ. Neurology of the newborn. Major Probl Clin Pediatr. 1981; 22: 1-648.
Rey E, Radvanyi-Bouvet MF, Bodiou C, Richard MO, Torricelli A, Walti H, et al. Intravenous lidocaine in the treatment of convulsions in the neonatal period: monitoring plasma levels. Ter Drug Monit. 1990; 12 (4): 316-20.
Glass HC, Kan J, Bonifacio SL, Ferriero DM. Neonatal Seizures: Treatment Practices Among Term and Preterm Infants. Pediatr Neurol. 2012; 46 (2): 111-5.
Ward RM, Kern SE. Clinical trials in neonates: a therapeutic imperative. Clin Pharmacol Ter. 2009; 86 (6): 585-7.
Perković Benedik M, Neubauer D. Epileptični status. Ljubljana: Univerza v Ljubljani, Medicinska fakulteta, Katedra za pediatrijo, Podiplomski študij otroške nevrologije, 2005. (Knjižnica otroške nevrologije; 2005, 9).
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003; 349 (12): 1157-67.
van den Anker JN. Developmental pharmacology. Dev Disabil Res Rev. 2010; 16 (3): 233-8.
Rang HP, Dale MM, Ritter JM, Flower RJ, G. H. Pharmacology. 7 ed. Edinburgh, London: Churchill Livingstone; 2012.
Neuropharmacology of Antiepileptic Drugs. In: Bromfeld EB, Cavazos JE, Sirven JI, editors. An Introduction to Epilepsy. West Hartford: American Epilepsy Society; 2006.
Ben-Ari Y. Te GABA excitatory/inhibitory developmental sequence: a personal journey. Neuroscience. 2014; 279: 187-219.
Nardou R, Ferrari DC, Ben-Ari Y. Mechanisms and effects of seizures in the immature brain. Semin Fetal Neonatal Med. 2013; 18 (4): 175-84.
Dunah AW, Yasuda RP, Wang YH, Luo J, Davila-Garcia M, Gbadegesin M, et al. Regional and ontogenic expression of the NMDA receptor subunit NR2D protein in rat brain using a subunit-specifc antibody. J Neurochem. 1996; 67 (6): 2335-45.
McNamara J. Pharmacotherapy of the Epilepsies. In: Brunton L, Chabner B, Knollmann B, editors. Goodman and Gilman’s Te Pharmacological Basis of Terapeutics. 12 ed. New York: McGraw-Hill Education; 2011.
Rener-Primec Z, V. B. Valproate-related erythrodermia with reversible encephalopathy: a rare but serious adverse reaction, case report. Acta Dermatovenerol APA. 2014 (23): 35-7.
Riikonen R, Rener-Primec Z, Carmant L, Dorofeeva M, Hollody K, Szabo I, et al. Does vigabatrin treatment for infantile spasms cause visual feld defects? An international multicentre study. Dev Med Child Neurol. 2015; 57 (1): 60-7.
Hines RN. Te ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ter. 2008; 118 (2): 250-67.
Lee SM, Chung JY, Lee YM, Park MS, Namgung R, Park KI, et al. Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Arch Dis Child. 2012; 97 (6): 569-72.
Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics. 2005; 15 (10): 677-85.
Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007; 48 (7): 1223-44.
Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia. 2002; 43 Suppl 3: 53-9.
Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006; 61 (3): 246-55.
Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer SE, Lee MTM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing. Clin Pharmacol Ter. 2014; 96 (5): 542-8.
Leckband SG, Kelsoe JR, Dunnenberger HM, George AL, Jr., Tran E, Berger R, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ter. 2013; 94 (3): 324-8.
Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Terapeutic Strategies. Epilepsia. 2008; 49 (7): 1239-76.
Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T, et al. Terapeutic drug monitoring of the newer antiepileptic drugs. Ter Drug Monit. 2003; 25 (3): 347-63.
Perucca E. Designing clinical trials to assess antiepileptic drugs as monotherapy : difculties and solutions. CNS drugs. 2008; 22 (11): 917-38.
Bittigau P, Sifringer M, Genz K, Reith E, Pospischil D, Govindarajalu S, et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA. 2002; 99 (23): 15089-94.
Neubauer D, Soltirovska-Salamon A, Osredkar D, Paro Panjan D. Management of refractory neonatal seizures. Res Rep Neonatol. 2014; 4: 17-29.
Milosheska D, Vovk T, Grabnar I, Roskar R. Simple and sensitive high performance liquid chromatography method with fluorescence detection for therapeutic drug monitoring of topiramate. Acta chim Slov. 2015; 62 (2): 411-9.
Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010; 8 (3): 254-67.
Milosheska D, Grabnar I, Vovk T. Dried blood spots for monitoring and individualization of antiepileptic drug treatment. Eur J Pharm Sci. 2015; 75: 25-39.
Milosheska D, Grabnar I, T. V. Terapevtsko spremljanje koncentracij lamotrigina in njegovega presnovka 2-N glukuronida s pomočjo posušenih krvnih madežev. Farm Vestn. 2015; 66.
Shellhaas R. Treatment of Neonatal Seizures 2015 [Available from: http://www.uptodate.com/contents/treatment-of-neonatal-seizures.]
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
